super aspirin

A popular term for the next generation of analgesics—e.g., Cox-2 inhibitors (Vioxx and Celebrex)—and antiplatelet GP IIb/IIIa receptor antagonists—e.g., orbofiban, sibrafiban, xemilofiban—which reduce inflammation and pain. They were heralded as being better than regular aspirin in relieving arthritic pain, with fewer side effects. However, the use of many such agents has been associated with a doubling of strokes and heart attacks and many have been pulled from the market

super aspirin

Cardiology A popular term for any agent–eg, antiplatelet GP IIb/IIIa receptor antagonist–orbofiban, sibrafiban, xemilofiban; SA relieves angina and ↓ risks of acute MI, but may be less effective than aspirin in preventing blood clotting post coronary angioplasty. See Aspirin, Lamifiban. Cf Baby aspirin.
References in periodicals archive ?
BYU's suit claimed that chemistry professor Daniel Simmons discovered the COX-2 enzyme in the early Cy90s, allowing for the development of "super aspirin," which would treat inflammation with fewer gastrointestinal side effects.
London, March 10 ( ANI ): Scientists have developed a potent "super aspirin" that can cause cancer cells to self-destruct.
Antiplatelets like aspirin and clopidogrel (a "super aspirin," trade name: Plavix) teamed up with coumadin can raise bleeding risks.
A NEW super aspirin is being tested as a possible anti-cancer drug.
The first drug to locate and inhibit enzymes that cause pain and inflammation without the accompanying gastrointestinal side effects of other pain relievers, the so-called "super aspirin" is known as Celebra in Brazil, where it has grabbed 10% of the market since April 1999.
The compound TO5, made from the venom, has had the toxic parts removed and now it acts as a super aspirin. It reduces the incidents of heart attack in high risk groups by 50 per cent.
Vioxx, a painkiller, received a boost last month when an advisory panel to the Food and Drug Administration recommended the agency approve the so-called super aspirin as an arthritis treatment.
(1) Enthusiasm for cox-2 inhibitors has even surfaced in the lay press, with such titles as: "Super Aspirin" in The New Yorker, (2) "Building a Better Aspirin" in Science, (3) and "A Revolution in Pain Relief?" in Business Week.
The drug, which Merck is marketing under the name Aggrastat, is being billed as a "super aspirin" to prevent blood clots.
The research team found that only two per cent of Britain's heart patients are treated with new super aspirin drugs compared with 34 per cent in Germany.
A New type of super aspirin could give hope to thousands of bowel cancer patients.
Researchers at Duke University Medical Center, Durham, N.C., think they know why glycoprotein IIb/IIIa platelet inhibitor drugs, collectively known as "super aspirins," produce only modest benefits for patients with acute coronary syndromes--they are often being used on patients who only can gain very little benefit.